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clinical rational for lumbar fusion surgery. Patients who underwent a ALIF, PLF or
T/PLIF with stand-alone DDD had significantly lower total payments and signifi-
cantly shorter LOS, while patients with DDD and additional back diagnoses had
significantly higher total payments and longer LOS compared to patients who un-
derwent an ALIF, PLF, or T/PLIF without a comorbid diagnosis of DDD.
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OBJECTIVES: Compare resource utilization and medical charges among patients
who had an anterior lumbar interbody fusion (ALIF), posterior lumbar interbody
fusion (PLF), or transforaminal posterior lumbar interbody fusion (T-PLIF) and a
subsequent revision surgery to those without such a revision surgery. METHODS:
The MedStat MarketScan databases from 2006 - 2009 were utilized for this retro-
spective analysis. Patients were included if had a ALIF, PLF, or T-PLIF and had
continuous insurance coverage for 2 years post procedure. Revision patients were
then matched to non-revision patients at a 2:1 ratio based upon type of initial
procedure, year of birth, sex, and region of residence Medical payments and re-
source utilization were compared between the two cohorts using t-statistics for
continuous variable and chi-square statistics for categorical variables. RESULTS: In
the 2 years post procedure, patients with a subsequent revision were significantly
more likely to visit a physical therapist (92% v 62%; P0.0001), receive an epidural
steroid injection (58% v 47%; P0.0074), or visit the emergency room with a diag-
nosis of back pain (20% v 9%; P0.0001). The average cost the initial surgery was
similar among the two cohorts ($39,925 v $38,341; P0.6422) while the mean cost
associated with a revision surgery was $35,296 (std dev$32,814). Total payments
for the two cohorts, ignoring the cost of the initial procedure was $33,180 for pa-
tients who did not have a subsequent revision, and $89,770 for patients with a
subsequent revision (P0.0001). These differences translate into a $56,590 cost
premium associated with a revision surgery – 62% of which can be accounted by the
revision surgery itself. CONCLUSIONS: Revision surgery was associated with sig-
nificantly more resource utilization post initial surgery. Comparing costs among
the two groups reveal a significant cost premium associated with revision surgery
and that such costs extended beyond the cost of the revision surgery itself.
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OBJECTIVES: Tuberous sclerosis complex (TSC) is a rare genetic disorder charac-
terized by benign tumor growth in multiple organs. TSC’s subsequent and varied
impacts on patients are typically treated by many different types of procedures.
This study aimed to assess the principal clinical manifestations imposed by the
disease and consequent major types of health care resource utilization experi-
enced among TSC patients in the United States (US). METHODS: An Institutional
Review Board-approved Internet-based survey of US TSC patients and caregivers
solicited information on prevalence of manifestations, disease management, and
impact on patients. Descriptive statistics were calculated. RESULTS: Of the 380
initial respondents, 53% were patients and 47% were caregivers. Surveys provided
data on 380 patients, of whom 59% were female and the mean age was 30.4 years
(SD: 17.3; median: 32.5). The majority of patients reported experiencing skin lesions
(53%) while seizures, cognitive concerns, cerebral tumors, angiomyolipomas (AML),
and subependymal giant cell astrocytomas (SEGA) were reported by 46%, 36%, 26%,
23%, and 21%, respectively. Ninety patients (24%) reported only one manifestation
of TSC, while 18%, 14%, and 38% reported 2, 3, or 4 or more. Over half of patients
(52%) had some type of TSC-related surgery including but not limited to brain
surgery (33%), embolization (12%), nephrectomy (7%), kidney transplant (6%), and
laser surgery (12%). Patients with SEGAs reported the highest level of brain surgery
(55%). Among patients with AMLs, embolization for kidney lesions (28%), nephrec-
tomy (12%) and kidney transplant (8%) were reported. CONCLUSIONS: In this anal-
ysis of initial respondents, TSC presents significant, and varied, epidemiological
and clinical burden in the US. Patients with SEGA and AMLs seemed to experience
the highest rates of invasive procedures among all patients with TSC.
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OBJECTIVES: The number of performed heart transplantations per year are well
published and can easily be accessed. Nevertheless, there are no exact figures on
the prevalence and incidence of patient survival after heart transplantation in
Germany, although these patients have high health care needs. Purpose of this
study was to generate these missing figures for the past and present as well as
taking an outlook into the future development until 2030. METHODS: Primarily
based on statistics from the Federal Statistical Office and liver transplant quality
reports of the German AQUA-Institute, relevant parameters and data were identi-
fied and used to develop an epidemiological model. Key drivers of the model are
yearly patient survival rates as well as growth rates of performed liver transplan-
tations. The model starts in 1987 and is able to predict the future development of
the cumulative liver transplant patient population until the year 2030. To account
for uncertainty, a 1.000 replication Monte-Carlo-Simulation with random samples
within published ranges of the input parameters was run. RESULTS: According to
our model currently (2012) about 7.773 (95% Confidence interval: 7.701 – 7.844)
patients with prior liver transplantation live in Germany. Until 2030 the model
estimates an increase of the population size to 17.490 (95% CI: 17.105 – 17.875)
people. The number of performed liver transplantations is estimated at 3.068 (95%
CI: 2.988 – 3.148) in 2030. CONCLUSIONS:With current assumptions the liver trans-
plant patient population size will continuously grow. The growth of this population
will primarily be limited by available organs for transplantation.
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OBJECTIVES: The number of performed heart transplantations per year are well pub-
lished and can easily be accessed. Nevertheless, there are no exact figures on the preva-
lence and incidence of patient survival after heart transplantation in Germany, although
these patients have high health care needs. Purpose of this study was to generate these
missing figures for the past and present as well as taking an outlook into the future de-
velopment until 2030.METHODS: Primarily based on statistics from the Federal Sta-
tistical Office and heart transplant quality reports of the German AQUA-Institute
relevant parameters and data were identified and used to develop an epidemiolog-
ical model. Key drivers of the model are yearly patient survival rates as well as
growth rates of performed heart transplantations. The model starts in 1980 and is
able to predict the future development of the cumulative heart transplant patient
population until the year 2030. To account for uncertainty, a 1.000 replication Mon-
te-Carlo-Simulation with random samples within published ranges of the input
parameters was run. RESULTS:According to our model currently (2012) about 4.072
(95% Confidence interval: 4.028 – 4.116) patients with prior heart transplantation
live in Germany. Until 2030 the model estimates a decrease of the population to
3.028 (95% CI: 2.980 – 3.077) people. Peak number of patients after heart transplan-
tation was estimated at 2007: 4.225 (95% CI: 4.192 – 4.257). The number of performed
heart transplantations is estimated at 266 (95% CI: 261-271) in 2030.CONCLUSIONS:
Even though the peak number of patients with heart transplants according to our
model has occurred in the past, still a considerable heart transplant patient popu-
lation is living at Germany and seeking health care services for their needs.
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INTRODUCTION: Evidence based medicine (EBM) is frequently used as the basis for
clinical guidelines and reimbursement recommendations. The hierarchy of evi-
dence is: Level I - randomized controlled trials (RCTs); Level II - nonrandomized
cohort studies; Level III - case control studies, Level IV - case series, and Level V -
expert opinion. RCTs are generally required when developing clinical guidelines or
reimbursement recommendations for drugs.OBJECTIVES:The purpose of this case
review is to illustrate an application of EBM to an innovative surgical procedure and
highlight how the recommendations for use changed with new evidence.
METHODS: NICE guidelines for arthroscopic surgery for femoro-acetabular im-
pingement were reviewed. This case study was selected because the treatment
modality represents a new surgical technology in which guidelines for coverage
recommendations, first promulgated in 2007, were later changed in 2011, illustrat-
ing the impact of additional evidence generation. RESULTS: In 2007, efficacy evi-
dence considered by NICE were two case series, with 158 and 10 patients respec-
tively. In 2011, efficacy evidence considered by NICE covered 1126 patients from 3
non-randomized controlled studies (none compared with natural history or non-
arthroscopic surgical techniques), 5 case series (with 100 to 200 hips), and 1 case
report. Twenty-two smaller case series were also identified. In 2011, four out of five
specialist advisors viewed the procedure as established while one advisor consid-
ered the efficacy and safety still to be uncertain. In 2007, NICE concluded “current
evidence . . . does not appear adequate for this procedure to be used without special
arrangements for consent and for audit or research” while in 2011 NICE concluded
“current evidence. . ... is adequate in terms of symptom relief in the short and
medium term.” CONCLUSIONS: For innovative surgical procedures in the UK, non-
randomized controlled studies and case series, supported by specialist recommen-
dation, may be sufficient for a positive recommendation by NICE.
DISEASE-SPECIFIC STUDIES
CANCER - Clinical Outcomes Studies
PCN1
USE OF THE 5-HT3-RA ANTIEMETICS IN THE PREVENTION AND TREATMENT
OF RADIATION INDUCED NAUSEA AND VOMITING
Knoth RL1, Faria C1, Chang E2, Broder M2
1Eisai, Inc., Woodcliff Lake, NJ, USA, 2Partnership for Health Analytic Research, Beverly Hills,
CA, USA
A408 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
